JPWO2024085166A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2024085166A5 JPWO2024085166A5 JP2024551825A JP2024551825A JPWO2024085166A5 JP WO2024085166 A5 JPWO2024085166 A5 JP WO2024085166A5 JP 2024551825 A JP2024551825 A JP 2024551825A JP 2024551825 A JP2024551825 A JP 2024551825A JP WO2024085166 A5 JPWO2024085166 A5 JP WO2024085166A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- cldn4
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022167362 | 2022-10-19 | ||
| JP2022167362 | 2022-10-19 | ||
| PCT/JP2023/037616 WO2024085166A1 (ja) | 2022-10-19 | 2023-10-18 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2024085166A1 JPWO2024085166A1 (https=) | 2024-04-25 |
| JPWO2024085166A5 true JPWO2024085166A5 (https=) | 2025-06-27 |
| JP7730432B2 JP7730432B2 (ja) | 2025-08-27 |
Family
ID=90737914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551825A Active JP7730432B2 (ja) | 2022-10-19 | 2023-10-18 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4606384A1 (https=) |
| JP (1) | JP7730432B2 (https=) |
| KR (1) | KR20250089513A (https=) |
| CN (1) | CN119997975A (https=) |
| AU (1) | AU2023365438A1 (https=) |
| CL (1) | CL2025001156A1 (https=) |
| IL (1) | IL319946A (https=) |
| MX (1) | MX2025004457A (https=) |
| TW (1) | TW202426503A (https=) |
| WO (1) | WO2024085166A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026042803A1 (ja) * | 2024-08-21 | 2026-02-26 | アステラス製薬株式会社 | がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| JPWO2008114733A1 (ja) | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | 抗Ｃｌａｕｄｉｎ−４抗体 |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| PL2904011T3 (pl) | 2012-10-02 | 2018-01-31 | Bristol Myers Squibb Co | Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka |
| AU2015244814B2 (en) * | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| EP3445788B1 (en) * | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| CA3174094A1 (en) * | 2020-03-31 | 2021-10-07 | Shinya Ishii | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| AU2022262542A1 (en) * | 2021-04-22 | 2023-11-02 | Astellas Pharma Inc. | Anti-cldn4/anti-cd137 bispecific antibody |
-
2023
- 2023-10-18 JP JP2024551825A patent/JP7730432B2/ja active Active
- 2023-10-18 CN CN202380073096.1A patent/CN119997975A/zh active Pending
- 2023-10-18 AU AU2023365438A patent/AU2023365438A1/en active Pending
- 2023-10-18 EP EP23879809.4A patent/EP4606384A1/en active Pending
- 2023-10-18 IL IL319946A patent/IL319946A/en unknown
- 2023-10-18 KR KR1020257015107A patent/KR20250089513A/ko active Pending
- 2023-10-18 TW TW112139704A patent/TW202426503A/zh unknown
- 2023-10-18 WO PCT/JP2023/037616 patent/WO2024085166A1/ja not_active Ceased
-
2025
- 2025-04-15 MX MX2025004457A patent/MX2025004457A/es unknown
- 2025-04-16 CL CL2025001156A patent/CL2025001156A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10913796B2 (en) | Antibodies targeting Fc receptor-like 5 and methods of use | |
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| JP2023539245A5 (https=) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2021503455A5 (https=) | ||
| JP2023506184A5 (https=) | ||
| JP2017536341A5 (https=) | ||
| CN112409488B (zh) | 针对多种冠状病毒的单克隆抗体及应用 | |
| JP2021515798A5 (https=) | ||
| JP2023543031A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2018518540A5 (https=) | ||
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| JP2022545647A5 (https=) | ||
| JP2021524478A5 (https=) | ||
| JP2023551027A5 (https=) | ||
| JP2021520832A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| JP2021530244A5 (https=) | ||
| JP2023529842A5 (https=) | ||
| JP2023511898A5 (https=) | ||
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2023548529A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| JP2021520195A5 (https=) |